



Correction to: The relationship between diabetes, prostate-specific antigen screening tests, and prostate cancer

Eric A. Miller¹  · Paul F. Pinsky¹ · Dudith Pierre-Victor¹

Published online: 30 November 2018
© Springer Nature Switzerland AG 2018

Correction to: *Cancer Causes & Control* (2018) 29:907–914
<https://doi.org/10.1007/s10552-018-1067-3>

In the original publication of the article, the categories of PSA levels among the subpopulation of men diagnosed with prostate cancer were published incorrectly in Table 4. The corrected Table 4 is given in this Correction.

The original article can be found online at <https://doi.org/10.1007/s10552-018-1067-3>.

✉ Eric A. Miller
Eric.Miller2@nih.gov

¹ Division of Cancer Prevention, National Cancer Institute,
9609 Medical Center Drive, Rockville, MD 20850, USA

Table 4 Comparison of PSA levels at diagnosis and prostate tumor clinical stage by diabetes status among men in the subpopulation of men in the screening arm with cancers diagnosed during the screening phase

	Overall			Low/intermediate grade		
	Diabetes (<i>N</i> = 141)	No diabetes (<i>N</i> = 1,886)	<i>P</i> -value	Diabetes (<i>N</i> = 127)	No diabetes (<i>N</i> = 1,701)	<i>P</i> -value
Tumor stage, <i>n</i> (%)						
Clinical TNM T						
T1–T1c	83 (58.9)	1,101 (58.4)	0.004	77 (60.6)	1,020 (60.0)	<0.001
T2–T2c	50 (35.5)	751 (39.9)		42 (33.1)	660 (38.9)	
≥ T3	8 (5.7)	32 (1.7)		8 (6.3)	19 (1.1)	
Localized (I/II)	116 (82.3)	1,598 (84.7)	0.43	105 (82.7)	1,483 (87.2)	0.15
Advanced (III/IV)	25 (17.7)	288 (15.3)		22 (17.3)	218 (12.8)	
Mean PSA level at diagnosis, mean (SE)	7.68 (1.07)	6.73 (1.02)	0.08	7.40 (1.07)	6.36 (1.02)	0.04
Categorized PSA level						
0–10.0 ng/ml	86 (74.8)	1,242 (79.9)	0.06	80 (77.7)	1,148 (82.3)	0.04
10.1–20.0	15 (13.0)	212 (13.6)		12 (11.6)	177 (12.7)	
> 20.0	14 (12.2)	100 (6.4)		11 (10.7)	69 (5.0)	